Determinants of left ventricular hypertrophy and its progression in high-flux haemodialysis

被引:10
|
作者
Kong, CH [1 ]
Farrington, K [1 ]
机构
[1] Lister Hosp, Renal Unit, Stevenage SG1 4AB, Herts, England
关键词
left ventricular hypertrophy; haemodialysis; risk factors; hyperparathyroidism;
D O I
10.1159/000069155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To identify factors contributing to the development and progression of left ventricular hypertrophy (LVH) in patients on high-flux haemodialysis. Method Fifty patients without clinical cardiac disease underwent baseline echocardiography, related measurements and follow-up studies 6-12 months later. Results: Residual urea clearance was lower (0.7 1.1 vs. 2.2 2.4 ml/min; p = 0.034) while systolic blood pressure (162 +/- 21 vs. 147 +/- 11 mm Hg; p = 0.003), duration of dialysis dependence (38 +/- 37 vs. 17 +/- 13 months; p = 0.004) and interclialytic weight gain (1.98 + 0.84 vs. 1.32 + 1.08 kg; p = 0.026) were higher in those with LVH. Parathyroid hormone changed less in those whose LVH regressed (186 +/- 89 vs. 303 +/- 280 pg/ml; p = 0.032). Regression did not occur when parathyroid hormone was >300 pg/ml. ACE gene polymorphism did not affect LVH development or progression. Conclusion: Systolic hypertension, duration of dialysis dependence and high interclialytic weight gains promote LVH. Hyperparathyroidism retards LVH regression. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [41] Impact of high-flux haemodialysis on the probability of target attainment for oral amoxicillin/clavulanic acid combination therapy
    Hui, Katrina
    Patel, Kashyap
    Kong, David C. M.
    Kirkpatrick, Carl M. J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 (01) : 110 - 113
  • [42] Determinants of left atrial reservoir strain and diagnostic potential for cardiac amyloidosis in pathological left ventricular hypertrophy
    Inoue, Katsuji
    Nakao, Yasuhisa
    Saito, Makoto
    Kinoshita, Masaki
    Higashi, Haruhiko
    Yamaguchi, Osamu
    CARDIOVASCULAR ULTRASOUND, 2025, 23 (01)
  • [43] Reverse correlation between ankle-brachial index and left ventricular hypertrophy in patients on maintenance haemodialysis
    Fu, WC
    Ye, CY
    Mei, CL
    Rong, S
    Wang, WJ
    NEPHROLOGY, 2006, 11 (01) : 9 - 14
  • [44] Comparison of 24-hour and occasional blood pressure monitoring in haemodialysis patients with left ventricular hypertrophy
    Roithinger, X
    Punzengruber, C
    Wallner, M
    Berent, R
    Prischl, FC
    Kramar, R
    Pachinger, O
    WIENER KLINISCHE WOCHENSCHRIFT, 1996, 108 (12) : 358 - 362
  • [45] Modeling of high sodium intake effects on left ventricular hypertrophy
    Zhang, Yan
    Liou, William W.
    Gupta, Vishal
    COMPUTERS IN BIOLOGY AND MEDICINE, 2015, 58 : 31 - 39
  • [46] The determinants of left ventricular hypertrophy defined by Sokolow–Lyon criteria in untreated hypertensive patients
    R Antikainen
    T Grodzicki
    A J Palmer
    D G Beevers
    E C Coles
    J Webster
    C J Bulpitt
    Journal of Human Hypertension, 2003, 17 : 159 - 164
  • [47] The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy
    Mutlu, H
    Özhan, H
    Ökçün, B
    Okuyan, E
    Yigit, Z
    Erbas, C
    Küçükoglu, MS
    Gültekin, N
    Üner, S
    Erdine, S
    Güven, Ö
    BLOOD PRESSURE, 2002, 11 (01): : 53 - 55
  • [48] ECG in left ventricular hypertrophy: A change in paradigm from assessing left ventricular mass to its electrophysiological properties
    Bacharova, Ljuba
    JOURNAL OF ELECTROCARDIOLOGY, 2022, 73 : 153 - 156
  • [49] Fibroblast growth factor-23 as a possible cause of left ventricular hypertrophy and pulmonary hypertension in haemodialysis patients
    El-Adawy, Noussa Mahmoud
    Helmy, Amal Kamal
    Ismail, Tamer Taha
    Tawfik, Abd El Rahman Sayed
    Keryakos, Hesham Kamal Habeeb
    Abu Ela, Mostafa Ahmed El Sayed
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0H) : H2 - H2
  • [50] "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis)
    Peters, Matthew N.
    Seliger, Stephen L.
    Christenson, Robert H.
    Hong-Zohlman, Susie N.
    Daniels, Lori B.
    Lima, Joao A. C.
    de Lemos, James A.
    Neeland, Ian J.
    deFilippi, Christopher R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (04):